Dermatology

Barr receives approval for Isotretinoin Capsules USP, 30 mg

Published in Biotech Business Week, June 15th, 2006

Barr Pharmaceuticals, Inc., (BRL) announced that its subsidiary, Barr Laboratories, Inc., received approval from the U.S. Food & Drug Administration (FDA) for its application to manufacture and market Isotretinoin Capsules USP, 30 mg.

The company will launch the product immediately under the trade name Claravis. The company will now market the full line of Isotretinoin product strengths, including Claravis 10 mg, 20 mg, 30 mg and 40 mg capsules.

Claravis Capsules, 30 mg will compete with Ranbaxy's Sotret (Isotretinoin) Capsules USP, 30 mg that had total annual sales of approximately $15 million for the most recent 12 months ending March 2006, based...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2006-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry